Blog

Calgene

Off-Label Marketing Case Involving Calgene Survives Despite Defendants’ Motion to Dismiss

Earlier this month, a False Claims Act case against drug maker Calgene was unsealed, revealing allegations of off-label marketing with regard to its controversial cancer drug Thalomid. The case, in which the government opted not to intervene, has been subject to several months’ worth of procedural wrangling by both parties. [...]

By | 2018-03-27T10:13:13+00:00 July 30th, 2014|Healthcare Fraud|